A randomized, double-blind, placebo-controlled phase 2 study of brodalumab in patients with moderate-to-severe Crohn’s disease

The American Journal of Gastroenterology

from Gastroenterology via xlomafota13 on Inoreader http://ift.tt/2b6G4ea
via IFTTT